Jc. Martinez et al., MDM2 EXPRESSION IN LYMPHOID-CELLS AND REACTIVE AND NEOPLASTIC LYMPHOID-TISSUE - COMPARATIVE-STUDY WITH P53 EXPRESSION, Journal of pathology, 177(1), 1995, pp. 27-34
MDM2 and p53 immunohistochemical protein expression was analysed in ly
mphocytes and in reactive and neoplastic lymphoid tissue. Phytohaemagg
lutinin (PHA)-stimulated lymphocytes displayed MDM2 and p53 co-express
ion. In 8 of 8 tonsils, 24 of 24 Hodgkin's disease (HD), and 10 of 24
high-grade non-Hodgkin's lymphoma (HG-NHL) specimens, MDM2 paralleled
p53 nuclear expression in non-tumour and tumour cells. The number of p
ositive cells was greater and the staining intensity was stronger for
p53 than for MDM2. In another nine of the 24 HG-NHL cases studied, dis
sociated expression was observed, with high p53 expression and very lo
w or absent MDM2 expression. In five cases, both MDM2 and p53 were neg
ative. The eight low-grade NHL (LG-NHL) cases were also MDM2- and p53-
negative. MDM2 and p53 expression in PHA-activated lymphocytes and rea
ctive lymphoid tissue is probably an expression of opposing biological
signals regulating cell proliferation. Parallel MDM2 and p53 expressi
on in all HD and in 10 out of 24 HG/NHL cases may indicate that this g
rowth suppressive pathway is maintained in those cases. However, disso
ciated MDM2/p53 expression (nine cases) and the absence of expression
of both proteins (five cases) may represent examples of deregulation o
f this growth control pathway. These findings are in agreement with pr
evious in vitro studies in cell lines regarding the role of MDM2/p53 i
nteraction in the regulation of growth control and extend this observa
tion to normal lymphocytes and reactive lymphoid tissue, suggesting a
possible role for MDM2 deregulation in lymphomagenesis.